Seen in the press : Nasal sprays-Key insights for a successful device development to achieve bioequivalence requirementsMarch 7, 2018
Seen in the press: ‘Nasal sprays – Key insights for a successful device development to achieve bioequivalence requirements’ in BioScience Today
The last issue of BioScience Today features an article about Nemera’ bioequivalence device program. Through this article learn how Nemera has established a unique approach for developing devices in the nasal sprays field.
An observation of generics in the nasal spray market will reveal to the keen observer an opportunity. Whilst the overall nasal spray market is currently experiencing limited growth, the market share of generics is increasing at a much faster rate. Seeing this, Nemera has established a unique approach for developing devices in this field. This approach follows seven steps. Discover them in the article.
The full article:
- Nasal sprays – Key insights for a successful device development to achieve bioequivalence requirements
The full issue of the magazine:
Nemera is a world leader in the design, development and manufacturing of drug delivery devices for the pharmaceutical, biotechnology & generics industries.
Nemera’s services and products cover several key delivery routes: Ophthalmic, Nasal, Buccal, Auricular, Inhalation, Dermal/Transdermal and Parenteral.
Nemera always puts patients first, providing the most comprehensive range of devices in the industry, including off-the-shelf innovative systems, customized design development and contract manufacturing.